Split-Dose Administration Enhances Immune Responses Elicited by a mRNA/Lipid Nanoparticle Vaccine Expressing Respiratory Syncytial Virus F Protein
Year: 2022
Type: article
Source: Molecular Pharmaceutics
Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4306412079
